TBPH - Theravance Biopharma, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
20.78
-0.38 (-1.80%)
As of 11:49AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close21.16
Open21.20
Bid20.79 x 800
Ask20.81 x 1000
Day's Range20.68 - 21.33
52 Week Range15.72 - 31.54
Volume124,044
Avg. Volume460,633
Market Cap1.311B
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-4.35
Earnings DateMay 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.22
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors
    PR Newswire

    Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors

    Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the appointment of Deepika R. Pakianathan, Ph.D. to its Board of Directors. Since 2001, Dr. Pakianathan has served as a Managing Member at Delphi Ventures, a venture capital firm focused on biotechnology and medical device investments and leads the firm's biotechnology investment activities.

  • Hedge Funds Have Never Been More Bullish On Theravance Biopharma Inc (TBPH)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Theravance Biopharma Inc (TBPH)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

  • Theravance Doses First Patient in Phase II Coronavirus Study
    Zacks

    Theravance Doses First Patient in Phase II Coronavirus Study

    Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.

  • The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
    Benzinga

    The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy

    The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) (announced new clinical program focused on the development of NurOwn as a treatment for Alzheimer's disease) * Burning Rock Biotech Ltd (NASDAQ: BNR) (went public June 12) * Cardiff Oncology Inc (NASDAQ: CRDF) * ESSA Pharma Inc (NASDAQ: EPIX) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Kamada Ltd. (NASDAQ: KMDA) * Novavax, Inc. (NASDAQ: NVAX) * Passage Bio Inc (NASDAQ: PASG) * Pliant Therapeutics Inc (NASDAQ: PLRX) * Translate Bio Inc (NASDAQ: TBIO) * Twist Bioscience Corp (NASDAQ: TWST)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 24) * Genetron Holdings Ltd - ADR (NASDAQ: GTH) (went public Friday) * Vaccinex Inc (NASDAQ: VCNX)Stocks In Focus Merck's Keytruda Approved For Skin Cancer Merck & Co., Inc. (NYSE: MRK) said the FDA as approved Keytruda, its anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.In pre-market trading, Merck shares were down 0.65% to $75.38.UniQure Out-Licenses Investigational Late-Stage Hemophilia B Gene Therapy For Up To $2.05B Gene therapy company Uniqure NV (NASDAQ: QURE) said it has entered into a licensing agreement with CSL Behring, providing the latter with exclusive global rights to etranacogene dezaparvovec, uniQure's investigational gene therapy for patients with hemophilia B.The agreement provides for uniQure receiving a $450 million upfront cash payment and potentially up to $1.6 billion in payments based on regulatory and commercial milestones. The company is also eligible to receive tiered double-digit royalties in a range of up to a low-20s percentage of net product sales arising from the collaboration.UniQure said the proposed transaction will provide significant financial resources to advance and expand its pipeline of gene therapy candidates, anchored by AMT-130 in Huntington's disease, and to invest further in its leading gene therapy manufacturing and technology platform to support pipeline growth.The stock was down 16.39% at $52.60 premarket Thursday.La Jolla Agrees To Buy Tetraphase After protracted three-way wrangling, Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) clinched a definitive merger agreement to be bought by La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $43 million in upfront cash, plus potential future cash payments of up to $16 million pursuant to contingent value rights.Melinta, which had earlier agreed to buy Tetraphase, terminated the agreement, and was paid $1.15 million as a break-up fee.In after-hours trading, Tetraphase shares declined 1.85% to $2.65, while La Jolla gained 2.08% to $4.90.See also: The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions Theravance Doses First Patient In Phase 2 COVID-19 Study Theravance Biopharma Inc (NASDAQ: TBPH) said the first COVID-19 patient has been dosed in a Phase 2 study of TD-0903, its lung-selective, nebulized Janus kinase inhibitor in development for the potential treatment of hospitalized patients with acute lung Injury caused by COVID-19.Offerings HUTCHISON CHINA/S ADR (NASDAQ: HCM) announced that it has entered into a definitive agreement for the sale of $100 million of shares at $25 per ADS through a private placement to private equity firm General Atlantic.This fundraise could increase to $200 million through a warrant granted with a term of 18 months for a further $100 million in Chi-Med shares exercisable at a price per share equivalent to $30 per ADS, the company said. Erytech Pharma SA (NASDAQ: ERYP) announced the signing of an agreement with the Luxembourg-based European High Growth Opportunities Securitization Fund for issuing convertible notes valued up to a maximum of 60 million euros ($67.2 million) in the event of conversion of all the notes, subject to the regulatory limit of 20% dilution.View more earnings on IBBErytech said the financing line aims at improving its financial strength and extending its cash horizon for the next key development milestones.Xeris Pharmaceuticals Inc (NASDAQ: XERS) said it has commenced concurrent underwritten public offerings of $20 million in shares of its common stock and $60 million in aggregate principal amount of convertible senior notes due 2025. The company expects the net proceeds to finance the commercialization of Gvoke and repay a $20 million loan, among other things.The stock was down 19.96% at $4.25 premarket. Evelo Biosciences Inc (NASDAQ: EVLO) priced its underwritten public offering of 12 million shares of its common stock at $3.75 per share for gross proceeds of $45 million. All of the shares in the offering are to be sold by the company. The offering is expected to close on or about June 29.The stock was down 8.98% at $3.65 premarket. Nantkwest Inc (NASDAQ: NK) priced its underwritten public offering of 7.41 million shares, with 3.7 million shares to be priced at $9.50 per share and the remaining 3.7 million shares at $12.12 per share to its CEO and principal stockholder Dr. Patrick Soon-Shiong. The aggregate gross proceeds from the offering are expected to be approximately $80.1 million.In after-hours trading, the stock shed 9.39% to $11.Translate Bio said it has commenced an underwritten public offering of $125 million of its common stock. In addition, Shire, a subsidiary of Takeda Pharmaceutical Co Ltd (NYSE: TAK), is offering 6.825 million of its common stock in the offering. The company clarified that it will not receive any proceeds from the shares sold by Shire.Translate Bio shares were down 6.64% at $24.89 premarket Thursday.Magenta Therapeutics Inc (NASDAQ: MGTA) priced its underwritten public offering of 7.5 million shares of its common stock at $8 per share for gross proceeds of $60 million. All the shares earmarked for the offering are sold by the company.On The Radar PDUFA Dates The FDA is set to rule on Zogenix, Inc.'s (NASDAQ: ZGNX) NDA for Fintepla as a potential treatment candidate for seizures associated with Dravet syndrome.Earnings * Aethlon Medical, Inc. (NASDAQ: AEMD) (after the close)Related Link: Evoke Gets FDA Nod For Gimoti, A Nasally-Administered Gastroparesis Drug See more from Benzinga * The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact * The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19
    PR Newswire

    Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19

    Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced that the first COVID-19 patient has been dosed in a Phase 2 study of TD-0903. TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (JAKi) in development for the potential treatment of hospitalized patients with Acute Lung Injury (ALI) caused by COVID-19. The Company believes TD-0903 has the potential to inhibit the cytokine storm associated with ALI and prevent progression to Acute Respiratory Distress Syndrome (ARDS).

  • Moody's

    GSK Finance (No.3) plc -- Moody's assigns A2 rating to GSK Finance (No.3) plc's proposed exchangeable notes

    Moody's Investors Service ("Moody's") has assigned an A2 rating to GSK Finance (No.3) plc's new exchangeable senior unsecured notes due 2023. - the proposed exchangeable notes do not provide loss absorption, in part because they could not lead to new equity creation.

  • Benzinga

    Benzinga's Top Upgrades, Downgrades For June 15, 2020

    Upgrades * Berenberg changed the rating for Mondelez International Inc (NASDAQ: MDLZ) from Hold to Buy. For the first quarter, Mondelez International had an EPS of $0.69, compared to year-ago quarter EPS of $0.65. The stock has a 52-week-high of $59.96 and a 52-week-low of $41.19. Mondelez International's stock last closed at $50.73 per share. * Evercore ISI Group upgraded the stock for Public Storage (NYSE: PSA) from Underperform to In-Line. Public Storage earned $2.58 in the first quarter, compared to $2.53 in the year-ago quarter. The stock has a 52-week-high of $266.76 and a 52-week-low of $155.37. Public Storage's stock last closed at $196.34 per share. * Loop Capital changed the rating for RH (NYSE: RH) from Hold to Buy. RH earned $1.27 in the first quarter, compared to $1.85 in the year-ago quarter. The stock has a 52-week-high of $265.87 and a 52-week-low of $73.14. RH's stock last closed at $235.97 per share. * For Werner Enterprises Inc (NASDAQ: WERN), UBS upgraded the stock from Neutral to Buy. Werner Enterprises earned $0.40 in the first quarter, compared to $0.52 in the year-ago quarter. The stock has a 52-week-high of $46.95 and a 52-week-low of $28.71. Werner Enterprises's stock last closed at $39.87 per share. * For Apache Corp (NASDAQ: APA), Citigroup upgraded the stock from Neutral to Buy. For the first quarter, Apache had an EPS of ($0.13), compared to year-ago quarter EPS of $0.10. The stock has a 52-week-high of $33.77 and a 52-week-low of $3.80. Apache's stock last closed at $13.77 per share. * B. Riley FBR upgraded the stock for Six Flags Entertainment Corp (NYSE: SIX) from Neutral to Buy. Six Flags Entertainment earned ($1.00) in the first quarter, compared to ($0.82) in the year-ago quarter. The stock has a 52-week-high of $59.52 and a 52-week-low of $8.75. Six Flags Entertainment's stock last closed at $22.74 per share. * For FormFactor Inc (NASDAQ: FORM), Stifel upgraded the stock from Hold to Buy. FormFactor earned $0.33 in the first quarter, compared to $0.20 in the year-ago quarter. The stock has a 52-week-high of $28.58 and a 52-week-low of $14.34. FormFactor's stock last closed at $25.18 per share. * Morgan Stanley changed the rating for AmerisourceBergen Corp (NYSE: ABC) from Equal-Weight to Overweight. For the second quarter, AmerisourceBergen had an EPS of $2.40, compared to year-ago quarter EPS of $2.11. The stock has a 52-week-high of $102.99 and a 52-week-low of $72.06. AmerisourceBergen's stock last closed at $94.90 per share. * Piper Sandler upgraded the stock for Twilio Inc (NYSE: TWLO) from Neutral to Overweight. In the first quarter, Twilio showed an EPS of $0.06, compared to $0.05 from the year-ago quarter. The stock has a 52-week-high of $209.94 and a 52-week-low of $68.06. Twilio's stock last closed at $191.82 per share. * Piper Sandler upgraded the stock for Shopify Inc (NYSE: SHOP) from Neutral to Overweight. In the first quarter, Shopify showed an EPS of $0.19, compared to $0.09 from the year-ago quarter. The stock has a 52-week-high of $844.00 and a 52-week-low of $281.69. Shopify's stock last closed at $742.70 per share. * For Intel Corp (NASDAQ: INTC), KeyBanc upgraded the stock from Sector Weight to Overweight. In the first quarter, Intel showed an EPS of $1.45, compared to $0.89 from the year-ago quarter. The stock has a 52-week-high of $69.29 and a 52-week-low of $43.63. Intel's stock last closed at $59.33 per share. Downgrades * Atlantic Equities changed the rating for Advance Auto Parts Inc (NYSE: AAP) from Neutral to Underweight. For the first quarter, Advance Auto Parts had an EPS of $0.91, compared to year-ago quarter EPS of $2.46. The stock has a 52-week-high of $171.43 and a 52-week-low of $71.33. Advance Auto Parts's stock last closed at $135.81 per share. * For Kimco Realty Corp (NYSE: KIM), Evercore ISI Group downgraded the stock from In-Line to Underperform. Kimco Realty earned $0.37 in the first quarter, compared to $0.37 in the year-ago quarter. The stock has a 52-week-high of $21.86 and a 52-week-low of $7.45. Kimco Realty's stock last closed at $13.76 per share. * Evercore ISI Group downgraded the stock for Macerich Co (NYSE: MAC) from In-Line to Underperform. Macerich earned $0.81 in the first quarter, compared to $0.81 in the year-ago quarter. The stock has a 52-week-high of $35.94 and a 52-week-low of $4.81. Macerich's stock last closed at $9.77 per share. * Clarksons Platou downgraded the stock for Transocean Ltd (NYSE: RIG) from Buy to Neutral. For the first quarter, Transocean had an EPS of ($0.30), compared to year-ago quarter EPS of ($0.30). The stock has a 52-week-high of $7.28 and a 52-week-low of $0.76. Transocean's stock last closed at $2.20 per share. * Evercore ISI Group changed the rating for Ventas Inc (NYSE: VTR) from In-Line to Underperform. For the first quarter, Ventas had an EPS of $0.97, compared to year-ago quarter EPS of $0.99. The stock has a 52-week-high of $75.40 and a 52-week-low of $13.35. Ventas's stock last closed at $39.41 per share. Initiations * With a rating of Buy, HC Wainwright & Co. initiated coverage on Atara Biotherapeutics Inc (NASDAQ: ATRA). The price target is set at $25.00 for Atara Biotherapeutics. In the first quarter, Atara Biotherapeutics showed an EPS of ($1.20), compared to ($1.44) from the year-ago quarter. The stock has a 52-week-high of $22.59 and a 52-week-low of $4.52. Atara Biotherapeutics's stock last closed at $9.38 per share. * With a rating of Buy, Seaport Global initiated coverage on Edison International (NYSE: EIX). The price target is set at $70.00 for Edison Intl. Edison Intl earned $0.63 in the first quarter, compared to $0.63 in the year-ago quarter. The stock has a 52-week-high of $78.93 and a 52-week-low of $43.63. Edison Intl's stock last closed at $57.59 per share. * With a rating of Buy, HC Wainwright & Co. initiated coverage on KalVista Pharmaceuticals Inc (NASDAQ: KALV). The price target is set at $30.00 for KalVista Pharmaceuticals. For the third quarter, KalVista Pharmaceuticals had an EPS of ($0.52), compared to year-ago quarter EPS of ($0.23). The stock has a 52-week-high of $23.23 and a 52-week-low of $5.61. KalVista Pharmaceuticals's stock last closed at $10.41 per share. * With a rating of Buy, Seaport Global initiated coverage on Sempra Energy (NYSE: SRE). The price target is set at $142.00 for Sempra Energy. In the first quarter, Sempra Energy showed an EPS of $3.08, compared to $1.92 from the year-ago quarter. The stock has a 52-week-high of $161.87 and a 52-week-low of $88.00. Sempra Energy's stock last closed at $124.06 per share. * With a rating of Neutral, Rosenblatt initiated coverage on Synaptics Inc (NASDAQ: SYNA). The price target is set at $66.00 for Synaptics. For the third quarter, Synaptics had an EPS of $1.49, compared to year-ago quarter EPS of $0.83. The stock has a 52-week-high of $84.75 and a 52-week-low of $27.45. Synaptics's stock last closed at $62.61 per share. * With a rating of Equal-Weight, Morgan Stanley initiated coverage on Theravance Biopharma Inc (NASDAQ: TBPH). The price target is set at $30.00 for Theravance Biopharma. In the first quarter, Theravance Biopharma showed an EPS of ($1.14), compared to ($1.32) from the year-ago quarter. The stock has a 52-week-high of $31.54 and a 52-week-low of $15.35. Theravance Biopharma's stock last closed at $25.25 per share. * Jefferies initiated coverage on Staar Surgical Co (NASDAQ: STAA) with a Buy rating. The price target for Staar Surgical is set at $55.00. In the first quarter, Staar Surgical showed an EPS of $0.04, compared to $0.03 from the year-ago quarter. The stock has a 52-week-high of $44.91 and a 52-week-low of $23.20. Staar Surgical's stock last closed at $42.73 per share. * Citigroup initiated coverage on SelectQuote Inc (NYSE: SLQT) with a Buy rating. The price target for SelectQuote is set at $32.00. The stock has a 52-week-high of $29.00 and a 52-week-low of $25.28. SelectQuote's stock last closed at $27.45 per share. * With a rating of Outperform, RBC Capital initiated coverage on SelectQuote Inc (NYSE: SLQT). The price target is set at $32.00 for SelectQuote. The stock has a 52-week-high of $29.00 and a 52-week-low of $25.28. SelectQuote's stock last closed at $27.45 per share. * With a rating of Overweight, Atlantic Equities initiated coverage on Starbucks Corp (NASDAQ: SBUX). The price target is set at $95.00 for Starbucks. Starbucks earned $0.32 in the second quarter, compared to $0.60 in the year-ago quarter. The stock has a 52-week-high of $99.72 and a 52-week-low of $50.02. Starbucks's stock last closed at $76.38 per share. * With a rating of Equal-Weight, Morgan Stanley initiated coverage on Packaging Corp of America (NYSE: PKG). The price target is set at $93.00 for Packaging Corp of America. Packaging Corp of America earned $1.50 in the first quarter, compared to $1.98 in the year-ago quarter. The stock has a 52-week-high of $114.78 and a 52-week-low of $71.05. Packaging Corp of America's stock last closed at $98.95 per share. * Morgan Stanley initiated coverage on International Paper Co (NYSE: IP) with an Underweight rating. In the first quarter, International Paper showed an EPS of $0.57, compared to $1.11 from the year-ago quarter. The stock has a 52-week-high of $47.64 and a 52-week-low of $26.38. International Paper's stock last closed at $34.92 per share. * Jefferies initiated coverage on Glaukos Corp (NYSE: GKOS) with a Hold rating. The price target for Glaukos is set at $44.00. Glaukos earned ($0.44) in the first quarter, compared to ($0.04) in the year-ago quarter. The stock has a 52-week-high of $84.65 and a 52-week-low of $23.31. Glaukos's stock last closed at $38.65 per share. * Morgan Stanley initiated coverage on EPAM Systems Inc (NYSE: EPAM) with a Equal-Weight rating. The price target for EPAM Systems is set at $246.00. In the first quarter, EPAM Systems showed an EPS of $1.43, compared to $1.25 from the year-ago quarter. The stock has a 52-week-high of $248.27 and a 52-week-low of $151.97. EPAM Systems's stock last closed at $235.24 per share. * Needham initiated coverage on MKS Instruments Inc (NASDAQ: MKSI) with a Buy rating. The price target for MKS Instruments is set at $125.00. MKS Instruments earned $1.54 in the first quarter, compared to $1.12 in the year-ago quarter. The stock has a 52-week-high of $122.30 and a 52-week-low of $66.87. MKS Instruments's stock last closed at $104.00 per share. * Jefferies initiated coverage on SelectQuote Inc (NYSE: SLQT) with a Hold rating. The price target for SelectQuote is set at $29.00. The stock has a 52-week-high of $29.00 and a 52-week-low of $25.28. SelectQuote's stock last closed at $27.45 per share.See more from Benzinga * Morning Market Stats in 5 Minutes * Recap: Motorcar Parts of America Q4 Earnings * Earnings Scheduled For June 15, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound?
    Zacks

    Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound?

    Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Thomson Reuters StreetEvents

    Edited Transcript of TBPH earnings conference call or presentation 6-May-20 9:00pm GMT

    Q1 2020 Theravance Biopharma Inc Earnings Call

  • Theravance Biopharma Inc (TBPH) Q1 2020 Earnings Call Transcript
    Motley Fool

    Theravance Biopharma Inc (TBPH) Q1 2020 Earnings Call Transcript

    TBPH earnings call for the period ending March 31, 2020.

  • Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates
    Zacks

    Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates

    Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.

  • Theravance Biopharma (TBPH) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Theravance Biopharma (TBPH) Reports Q1 Loss, Tops Revenue Estimates

    Theravance Bio (TBPH) delivered earnings and revenue surprises of -7.55% and 10.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Here's What We Think About Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pay
    Simply Wall St.

    Here's What We Think About Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pay

    Rick Winningham became the CEO of Theravance Biopharma, Inc. (NASDAQ:TBPH) in 2014. This analysis aims first to...

  • Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020
    PR Newswire

    Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020

    Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its first quarter 2020 financial results and provide a business update after market close on Wednesday, May 6, 2020. An accompanying conference call and simultaneous webcast will be hosted at 5:00 p.m. ET (2:00 p.m. PT/9:00 p.m. GMT) that day.

  • Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19
    PR Newswire

    Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19

    Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced that the first healthy volunteer has been dosed in a Phase 1 study of TD-0903. TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (JAKi) in development for the potential treatment of hospitalized patients with Acute Lung Injury (ALI) caused by COVID-19. The Company believes TD-0903 has the potential to inhibit the cytokine storm associated with ALI and prevent progression to Acute Respiratory Distress Syndrome (ARDS).

  • Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis
    PR Newswire

    Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis

    Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the publication of a peer-reviewed paper summarizing positive results from completed Phase 1 clinical and preclinical studies of TD-1473, the Company's gut-selective pan-Janus kinase (JAK) inhibitor. The manuscript, which was published in the Journal of Crohn's and Colitis, highlights a broad collection of data demonstrating minimal systemic drug exposure, local target engagement, and trends toward reduced markers of ulcerative colitis disease activity following TD-1473 administration versus placebo.

  • Seth Klarman Dials Down Akebia Therapeutics Stake
    GuruFocus.com

    Seth Klarman Dials Down Akebia Therapeutics Stake

    Renowned guru slims position in biotech company that focuses on kidney disease Continue reading...

  • Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury
    PR Newswire

    Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury

    Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced that it is advancing TD-0903, a lung-selective nebulized Janus kinase inhibitor (JAKi) into clinical development to assess its utility in preventing the cytokine storm associated with Acute Lung Injury (ALI) in patients hospitalized due to COVID-19, with the ultimate goal of preventing progression to Acute Respiratory Distress Syndrome (ARDS).

  • Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump To 94
    Investor's Business Daily

    Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump To 94

    Theravance Biopharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

  • Seth Klarman Sees Bargains as the Market Heads Further Into Chaos
    GuruFocus.com

    Seth Klarman Sees Bargains as the Market Heads Further Into Chaos

    Baupost leader is also seeking more capital Continue reading...

  • Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes
    PR Newswire

    Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes

    Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" and together with its subsidiaries, the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the closing of a private placement of $400 million of non-recourse Triple II 9.5% fixed rate term notes. The notes are secured by a portion of the future payments the Company expects to receive related to royalties due on net sales of Trelegy Ellipta. The Company used a portion of the net proceeds from this transaction to repay in full the remaining outstanding balance of the $250 million Triple PhaRMASM 9.0% fixed rate term notes due 2033 and intends to use the remainder of the net proceeds to support continued execution of its key development programs.

  • Analysts Have Lowered Expectations For Theravance Biopharma, Inc. After Its Latest Results
    Simply Wall St.

    Analysts Have Lowered Expectations For Theravance Biopharma, Inc. After Its Latest Results

    A week ago, Theravance Biopharma, Inc. (NASDAQ:TBPH) came out with a strong set of full-year numbers that could...

  • Thomson Reuters StreetEvents

    Edited Transcript of TBPH earnings conference call or presentation 24-Feb-20 10:00pm GMT

    Q4 2019 Theravance Biopharma Inc Earnings Call

  • Theravance Biopharma Announces Presentations at Upcoming Investor Conferences
    PR Newswire

    Theravance Biopharma Announces Presentations at Upcoming Investor Conferences

    Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast Management presentations:

  • Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares
    PR Newswire

    Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares

    Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the pricing of its underwritten public offering of 5,500,000 ordinary shares at a price to the public of $27.00 per share. The gross proceeds to Theravance Biopharma from the offering are expected to be approximately $148.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Theravance Biopharma has granted the underwriters a 30-day option to purchase up to an additional 825,000 ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 14, 2020, subject to customary closing conditions.